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Alzheimer's disease is characterized by the self-assembly of tau and amyloid β proteins into oligomers and fibrils.
Tau protein assembles into paired helical filaments (PHFs) that constitute the neurofibrillary tangles observed in
neuronal cell bodies in individualswith Alzheimer's disease. Themechanismof initiation of tau assembly into PHFs
is not well understood. Here we report that a truncated 95-amino-acid tau fragment (corresponding to residues
297–391 of full-length tau) assembles into PHF-like fibrils in vitro without the need for other additives to initiate or
template the process. Using electron microscopy, circular dichroism and X-ray fiber diffraction, we have
characterized the structure of the fibrils formed from truncated tau for the first time. To explore the contribution of
disulfide formation to fibril formation, we have compared the assembly of tau(297–391) under reduced and
non-reducing conditionsand for truncated tau carrying aC322Asubstitution.Weshow that disulfidebond formation
inhibits filament assembly and that the C322A variant rapidly forms long and highly ordered PHFs.
Crown Copyright © 2017 Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Introduction
Alzheimer's disease (AD) is characterized by the
intracellular accumulation of insoluble neurofibrillary
tangles composed of tau protein and the ex-
tracellular deposition of amyloid plaques. Amyloid
plaques are composed predominantly of the amyloid
β peptide [1], while neurofibrillary tangles are
composed of paired helical filaments (PHFs), con-
sisting of a truncated fragment of tau protein
restricted to the repeat domain [2]. Tau and amyloid
β peptides self-associate in vitro to form fibrils that
share a cross-β core [3,4]. Oligomeric species of
tau have been implicated as being important in the
characteristic spread of neurofibrillary degeneration
throughout the brain and for the toxic effects leading
to neuronal dysfunction and death [5,6]. Several lines
of evidence point to the importance of neurofibrillaryht © 2017 Published by Elsevier Ltd. This
rg/licenses/by/4.0/).tau pathology being closely associated with demen-
tia in AD and other tauopathies [7–13].
Tau protein, encoded by the MAPT gene, is
expressed in the central nervous system as a family
of six isoforms. These arise by alternative mRNA
splicing and vary in length and in the content of three
or four tandem repeats of 31 or 32 amino acids in the
C-terminal domain [14]. Microtubules are essential
in morphogenesis, cell division, and intracellular
trafficking of organelles. At physiological concentra-
tions, tau proteins stabilize microtubules as tracks for
intracellular transport, but in excess, they interfere
with axonal transport [15]. Tau is also implicated in a
number of other cellular functions, such as signal
transduction and actin interaction and in the binding
of pericentomeric chromatin in the nucleus [16,17]. In
ADandother tauopathies, tau self-assembles through
the repeat domain to formPHFs and straight filaments
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3651PHFs formed by truncated tau(SFs). Structural characterization of PHFs isolated
from AD brain tissue has revealed that the fibers
display a distinct organisation of paired filaments that
either twist [18] or remain straight [3,19,20]. These
filaments are also known to share the structural
characteristics for amyloid, such as long unbranching
filaments and high β-sheet content, and they display
the characteristic cross-β pattern by X-ray fiber and
electron diffraction [3].
Several groups have investigated assembly
of full-length tau in vitro using addition of other
polyanionic molecules, such as heparin, RNA, or
proteoglycans, to nucleate assembly [21–23]. The tau
species making up the proteolytically stable structural
core of the PHF and its oligomeric precursors are
derived from a mixture of fragments derived from both
three- and four-repeat isoforms, but restricted to the
equivalent of three repeats in length with distinct
species originating from the three- and four-repeat
isoforms of tau [24]. Two of the fragments from
the three- and four-repeat isoforms terminate at the
C-terminus at Glu-391, with an N-terminus at amino
acid 297. The third derives from the first three repeats
of the four-repeat isoform and has N- and C-termini at
homologous positions [24,25]. The fragments termi-
nating atGlu-391 can bedetected specifically using the
antibody mAb423 [26], which has been shown to bind
to intra- and extracellular NFTs in AD brain tissue
[25,27,28]. The features of these 95-amino-acid-long
fragments represent the footprint of the pathological
tau–tau binding interaction which locks the repeat
domains into a characteristic proteolytically stable
conf igurat ion and one that is abnormally
phase-shifted with respect to the tubulin-binding
domains in this region of tau [25]. This templated
prion-like interaction propagates and is amplified
through repeated proteolytic digestion cycles [51]
and can be modeled within the cell milieu [29].
Full-length and truncated tau bind to the core tau
fragment with an estimated KD of 20 nM, and binding
is inhibited 10- to 50-fold by phosphorylation [30].
Recently, a cryo-electron microscopy structure of
PHFs isolated from AD brain has been reported [31].
The core structure of these filaments consists of
residues 306 to 378, and the structure can incorpo-
rate both three- and four-repeat tau isoforms. The
structure is an in-register parallel β-sheet formed by
a β-bend and β-helix motif, linked by β-strands [31].
In this study, we have used the truncated PHF-core
tau fragment, based upon the core of the PHF [18,32]
and which includes the PHF core region identified in
the recently reported PHF structure [31]. The truncat-
ed fragment comprises 95 amino acids corresponding
to residues 297–391 from the 441-residue tau isoform
(4R2N). It is termed dGAE, where d identifies the
N-terminal residue 297 andGAE, the three C-terminal
residues terminating with Glu-391, as described in
detail in Ref. [25]. dGAE was examined under non-
reducing and reducing conditions. The 95-amino-acidpeptide contains a single cysteine at position 322, and
we have compared the assembly of wild-type dGAE
with protein in which the Cys has been substituted
with Ala (dGAE-C322A). The dGAE protein self-
assembles into filaments that share the characteris-
tics of amyloid (β-sheet content, cross-β X-ray fiber
diffraction pattern) and that closely resemble the
PHFs isolated from AD brains. We have investigated
the contribution of disulfide formation of Cys322
and show that incubation in reducing conditions or
introducing a C322A substitution leads to enhanced
self-assembly and the production of long and highly
ordered PHFs.Results
Assembly of truncated tau protein
Recombinant truncateddGAE tauanddGAE-C322A
were expressed in bacteria and purified by ion-
exchange chromatography. Purified, soluble dGAE
(100 μM) was incubated in phosphate buffer (PB),
with and without 10 mM dithiothreitol (DTT).
dGAE-C322A was prepared in the same manner
(without DTT) and assembly into aggregates or
filaments was monitored using thioflavin-S (ThS)
fluorescence at intervals up to 48 h (Fig. 1). ThS has
been previously shown to give an enhanced intensity
when measuring tau assembly [33] and used to
quantify PHFs [29]. ThS fluorescence intensity for
reduced and non-reduced dGAE and dGAE-C322A
increased with time indicating the gradual assembly
into oligomers and filaments (Fig. 1a). ThS assays are
very similar to thioflavin T (ThT) and will detect
assembled structures above a certain threshold
(depending on concentration). As has been shown
frequently, ThT and ThS begin to show a signal at
time points where small oligomeric structures can be
observed by electron microscopy. The elongation of
the fibrils correlates with an increase in fluorescence
intensity. Indeed, we detect small oligomers by
transmission electron microscopy (TEM) at the same
time point as an increased ThS intensity. Each
spectrum showed a similar lag-phase length; the
final intensity of ThS fluorescence for dGAE-C322A
after 48 h was slightly lower than for dGAE. This may
reflect subtle changes in binding of ThS to the different
species formed. Tyrosine fluorescence was moni-
tored to follow changes in the environment of the
tyrosine residue during assembly and, again, the data
suggest similar assembly rates for non-reduced
dGAE and dGAE-C322A. In the presence of DTT,
the tyrosine fluorescence decreased more rapidly,
consistent with an alternative assembly pathway.
Circular dichroism (CD) spectra showed that the
dGAE transitioned from a mainly random coil confor-
mation, with a minimum at 198 nm, to one of
Fig. 1. Assembly of dGAE (100 μM) incubated in non-reducing and reducing conditions (with 10 mM DTT) and dGAE-C322A (100 μΜ) in PB (10 mM; pH 7.4).
(a) ThS fluorescence assay showing assembly of all three samples over 48 h. (b) Fluorescence from tyrosine decreases over time during assembly suggesting a
change in the environment of the tyrosine side-chain. Data expressed as mean ± S.E. (n = 3). (c) CD spectra of non-reducing and reducing dGAE and dGAE-C322A
over time for the whole sample (top) and in the separated supernatant and pellet fractions (below). The whole samples show a reduction in intensity of the random coil
signal (198 nm minimum) (see Fig. S1) and a relative increase in intensity at 218 nm with increased time. Following separation, random coil was observed in
the supernatant and β-sheet in the pellet. For the separated samples, the y axis is given in millidegrees as the unknown concentrations did not allow for conversion to
molar ellipticity.
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3653PHFs formed by truncated tauincreasing β-sheet conformation and reduced random
coil (Fig. 1c). Random coil dominates the signal in the
whole sample, so to investigate this further, samples
were centrifuged at 20,000g to separate the superna-
tant and pellet and CD was performed on the
separated samples (Fig. 1c). This revealed that the
suspended pellet contains protein showing a strong
red-shifted β-sheet signal with a minimum at 226 nm,
while the supernatant contains protein that is predom-
inantly random coil with a strong minimum at 197 nm.
Under reducing conditions, dGAE gave a similar
spectral profile to non-reduced dGAE. dGAE-C322A
gave a very weak random coil signal in the superna-
tant fraction, suggesting a reduction in available
soluble random coil protein. The spectrum from the
dGAE-C322A pellet was unusual and contained
minima at 194 nm and 230 nm. To ensure that this
did not arise from alignment of fibrils giving rise to
linear dichroism [34], the cuvette was rotated 90°. The
spectrawere very similar, suggesting that this spectral
difference does arise from CD. A red-shifted signal to
230 nm for β-sheet has been observed previously for
elongated amyloid fibrils made from α-synuclein and
may arise from extended lengths of β-structure in long
fibrils [35]. To compare the assembly of dGAE, dGAE
with DTT and dGAE-C322A and to complement the
results of ThS and tyrosine fluorescence, the intensity
of the CD signal for the supernatant only, was plotted
against time (Fig. S1). These results suggest that
dGAE-C322A variant assembles more quickly than
dGAE under reducing conditions and that both
assemble more quickly than dGAE alone. Centrifuga-Fig. 2. TEM of dGAE (100 μM) incubated in non-reducing an
(100 μΜ) in PB (10 mM; pH 7.4). dGAE assembles slowly to fo
by 10-h incubation. dGAE-C322A forms long fibrils that assoction of the samples results in difficulties in measuring
protein concentrations in pellet and supernatant.
Therefore, Advanced Protein Assay was used to
compare the concentration of protein in the pellet and
supernatant for dGAE and dGAE-C322A after incu-
bation of 48 h (Fig. S2). The results confirmed that
less dGAE C322A remains in the supernatant
compared to dGAE, supporting the view that C322A
assembles more effectively than dGAE.
TEM was performed to compare the morphology of
the dGAEsamples at timepoints from0 to 48 h (Fig. 2).
Assembly of dGAE was observed under non-reducing
conditions showing the formation of small round
particles, which developed into slightly elongated and
laterally associated fibers after 10-h incubation and
which did not elongate further by 48 h. In contrast,
dGAE incubated with DTT under reducing conditions
formed distinct fibrillar structures by 4 h, which
continued to elongate up to 48 h. dGAE-C322A formed
elongated structures by 4 h and numerous long fibrils
by 24 h, which associated laterally by 48 h. The ThS
fluorescence assay suggested that the assembly
kinetics were similar for the three protein samples
(Fig. 1a). However, TEM revealed significant differ-
ences in elongationandmorphologies at the incubation
time points examined (Fig. 2).
SDS-PAGE was conducted on samples treated in
the same way as for fluorescence assays and TEM
(Fig. 3). The whole sample was compared with
separated supernatant and pellet fractions. dGAE
ran as a doublet with mobilities of 10/12 kDa and a
doublet with mobilities of 20/24 kDa (see Fig. 3a,d reducing conditions (with 10 mMDTT) and dGAE-C322A
rm small elongated fibers, while reduced dGAE forms fibrils
iate laterally by 48 h. The scale bars represent 200 nm.
Fig. 3. SDS-PAGE and immunoblot of dGAE (100 μM) in (a) non-reducing and (b) reducing conditions (with 10 mMDTT) and (c) dGAE-C322A (100 μM). Each set of
panels shows the results of Coomassie blue-stained SDS-PAGE gels (left) and immunoblot, using T22 anti-tau oligomer antibody (right), for the entire sample (whole)
and the fractionated supernatant (sup) and pellet. Panel a shows an inset to highlight the positions of the doublet bands with reduced intensity. (d) Dot immunoblot for
protein samples developed using T22 [36].
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3655PHFs formed by truncated tauinset). Since the dGAE fragment has a theoretical
molecular weight of 10.27 kDa, 10 kDa is likely to
represent the monomer and 20 kDa, the correspond-
ing dimer. The 12- and 24-kDa species are likely
to represent alternative folding configurations of the
dGAE monomer and dimer, respectively, having
retarded gel mobility. After 48 h, the intensity of the
bands in the whole sample was decreased and the
bands in the supernatant appeared to be similar,
but with markedly decreased dimer content. The
pellet was enriched selectively for the 12- and 24-kDa
species as well as for some weaker bands migrating
at 37–50 kDa, suggesting the presence of higher-
molecular-weight oligomers. The data suggest that
the dGAE fragment is able to exist in two SDS-
resistant conformations with different gel mobilities
both as monomers and as dimers. The selective
enrichment in the pellet of the 12- and 24-kDa
species suggests that only one of the two conforma-
tions of dGAE is competent to aggregate into fibrils.
To confirm that dGAE with DTT remained reduced
following incubation for 48 h, free thiols were
detected using Iodoacetimide-Oregon Green 488
(IAA-OG) assay (see Supplementary Information for
methods). The results confirmed that the cysteine
thiols remained free following incubation (Fig. S3).
Immunoblotting was conducted using T22, an
oligomer-specific antibody [36] to gain more informa-
tion about the different mobility species. T22 bound
selectively with the 12- and 24-kDa species in the
pellet, but not with the more abundant 10-kDa
monomer present in the supernatant. T22 also labeled
higher-molecular-weight species at around 50 kDa in
the pellet.
dGAE incubated under reducing conditions pro-
duced intense 10- and 12-kDa monomer bands at 0
and 48 h, but less of the corresponding dimers than
seen in the absence of DTT. Coomassie blue staining
also revealed non-migrating species of very-high-
molecular-weight species in the wells. The monomer
band remaining in the supernatant was substantially
reduced and restricted to the species with 10-kDa
mobility. The pellet contained both monomeric and
dimeric species, corresponding exclusively to the 12-
and 24-kDa variant. Comparison of these gels with
those from non-reduced dGAE preparations suggests
that the prevention of disulfide bond formation by the
incubation with DTT facilitates the aggregation of the
12- and 24-kDa assembly-competent variants, leaving
the 10-kDamonomer in the supernatant fraction. Also,
incubation with DTT favors the formation of very-
high-molecular-weight species which are either SDS
insoluble or too large to enter the gel. Interestingly,
immunoblotting again revealed preferential binding of
T22 to the 12- and24-kDa species, andnot the 10- and
20-kDa variants seen by Coomassie staining in the
whole preparation and in the supernatant fraction.
dGAE-C322A (Fig. 3) showed a predominant
12-kDamonomer and a less intense 10-kDamonomerat 0 h. After 48 h, the 12-kDa species was enriched
in the pellet and the 10-kDa species enriched in the
supernatant. Dimer formation was less than seen
either for native dGAE fragment or following incubation
in DTT, and again corresponded to the 24-kDa
species. Immunoblotting showed that T22 reactivity
was restricted to the 12-kDa species in the pellet
with no binding to the 10-kDa species predominating
in the supernatant fraction at 48 h. As a control,
dGAE-C322A was also separated by SDS-PAGE in
the presence of DTT and no change in the mobility
was observed (data not shown).
In contrast to samples separated by SDS-PAGE,
dot immunoblotting showed reactivity with T22 in all
three samples at 0 h, and this is likely to correspond
to the 12-kDa species. The intensity of T22 binding
reduced after 48-h incubation in the whole and
supernatant sample, and there was no binding of
T22 to the pellet (Fig. 3b). This suggests that the
12-kDa band is in an oligomer-like conformation and
that, following filament assembly, there is occlusion
of the T22 epitope(s) leading to loss of T22 binding.
Collectively, the results of ThS, tyrosine fluores-
cence, TEM, and SDS-PAGE show that Cys-322 is
unnecessary for filament assembly and that reduc-
tion of disulfide bonds, or substitution of Cys with Ala,
promotes assembly to form longer and larger fibrillar
structures, which sediment at low speed and that
these are composed predominantly of the 12-kDa
variant. Furthermore, the formation of a dimer in
reducing conditions is suggestive of an alternative
SDS-insoluble bond being formed in dGAE [37]. One
possibility is the formation of dityrosine,which remains
stable in reducing conditions [38].
X-ray fiber diffraction was performed for fibrils
formed after 48-h incubation and revealed that all
three proteins were able to form cross-β structures
characteristic of amyloid fibrils (Fig. 4). The diffrac-
tion patterns shared a sharp, strong 4.7-Å and a
10-Å reflection, although the pattern from dGAE was
poorly aligned due to the short fibrous structures
formed. However, the diffraction pattern from dGAE-
C322A showed a well-aligned fiber diffraction
pattern with clear 4.7-Å reflection on the meridian
and 9.5-Å reflection on the equator. A low-angle
diffraction signal close to the backstop was also
observed at approximately 28 Å, which may arise
from ordered packing of the filaments (Fig. 4, inset).
The patterns collected from the three fiber samples
were very similar, and no obvious differences can be
inferred from the patterns.
At 100 μM, dGAE forms only relatively short fibrillar
structures even after incubation of up to 48 h. To
investigate whether there is a concentration depen-
dent effect leading to different fibril morphologies,
dGAE was incubated at increasing concentrations
from 100 μM to 400 μM.
CD was used to examine the secondary struc-
tures of the dGAE at different concentrations in the
Fig. 4. X-ray fiber diffraction patterns from partially aligned fibrils. dGAE (100 μM) incubated in non-reducing and
reducing conditions (with 10 mM DTT) and dGAE-C322A (100 μΜ) in PB (10 mM; pH 7.4) washed in milliQ water before
alignment. The inset highlights the diffraction signals for dGAE-C322A to show the position of a 28-Å equatorial signal.
3656 PHFs formed by truncated tauseparated supernatant and pellet fractions. The CD
spectra of the supernatant indicated the presence
of random coil structure and signal intensities at
198 nm increased with concentration (Fig. S4),
suggesting that a proportion of protein remains in
solution. However, the CD spectra of dGAE pellet
from different starting concentrations varied consid-
erably. All spectra were consistent with a β-sheet
conformation, but the positions of the minima differed
slightly, probably reflecting differences in the super-
secondary structural content of the filamentous
structures in the pellet (Fig. 5a). ThS fluorescence
was measured over 24 h and assembly rates for
dGAE at low and high concentrations were com-
pared. The findings suggest that the elongation rate
increased with increased starting protein concentra-
tion (Fig. S5). TEM analysis showed changes in the
lateral association and twisting of the filaments.
Longer fibrils were observed at 250-μM concentra-
tion and at 300 μM, only long fibrils were observed
while the smaller elongated particles were absent. At
the highest concentration of dGAE tested (400 μM),
highly ordered filaments with a clearly paired arrange-
ment and a regular twist were observed (Fig. 5b).
The mean (±SD) width was 16.18 ± 1.59 nm and
7.61 ± 1.24 nm with an approximate periodicity of
73.3 ± 4.37 nm (distributions shown in Fig. S6).
In order to investigate whether the molecular
architecture of the filaments was dependent on con-
centration, X-ray fiber diffraction data were collected
from all fiber samples prepared over a range of
concentrations. Partially aligned fiber samples all
exhibited characteristic cross-β diffraction signals
(Fig. 5c, white and black arrows). The patterns were
very similar to one another, with some small differ-
ences in alignment of the meridional and equatorial
diffraction signals. TEM reveals differences in lateralpacking and length but X-ray fiber diffraction reveals
that the core structureswere similar in all samples and
consistent with the classical cross-β structure within
the core of the protofilaments [39].
TEMandX-ray fiber diffraction were used to explore
further whether there are any structural differences
between dGAE incubated in non-reducing and re-
ducing conditions at high concentrations (400 μM)
(Fig. 6). TEM showed that dGAE under both
conditions forms PHFs that have a helical periodicity
of around 80 nm. This is similar to the helical
periodicity observed for PHF isolated from AD tissue
[18,32,40,41]. The truncated protein was able to form
straight, paired filaments as well, although these were
less common than the PHF morphology (approxi-
mately 10:90 ratio of SF to PHF) (see Fig. S7). SFs
extracted from AD brain tissue constitute 5% of
filaments [42]. X-ray fiber diffraction data showed the
expected cross-β diffraction signals, but alignment
was insufficient for further analysis. This is likely to be
due to the very long filaments tangling and preventing
good fiber orientation. However, the patterns show no
evidence of any obvious differences between sam-
ples incubated with or without DTT.
Further analysis of the morphologies found in
non-reduced and reduced dGAE samples is shown
in Fig. 7. Non-reduced dGAE formed a majority of
PHFs with a helical repeat of 73.3 ± 4.37 nm, while
reduced dGAE formed PHFs with a helical repeat
of 65.0 ± 6.9 nm and diameters of 17.8 ± 1.19 nm
(wide) and 10.09 ± 2.42 nm (narrow). Occasionally,
wider filaments were observed with a diameter of
20 nm, which appeared to be composed of more
than one pair of filaments twisted together (Fig. 7).
Fewer filaments with longer repeats of 83 nm were
also observed. Overall, although the two samples
contained a range of different species, there was
Fig. 5. Characterization of dGAE fibrils. Fibrils were formed using different starting concentrations of protein, as indicated, and incubated at 37 °C with agitation
(700 rpm) for 48 h in PB (10 mM; pH 7.4). (a) Comparison between the CD spectra of supernatant and pellet fractions for each concentration of dGAE. The y axis is
given in millidegrees as the concentrations did not allow for conversion to molar ellipticity. The intensity at 198 nm increased with increasing concentration (see Fig. S4).
(b) dGAE fibril morphologies by TEM. The scale bars represent 200 nm (increased magnification panels included to highlight morphologies). (c) X-ray fiber diffraction
patterns from partially aligned filament samples formed by dGAE, at the starting concentration indicated, showing the classic “cross-β” pattern (4.7 Å meridional is
labeled with black arrow and 10–11 Å equatorial, with white arrow). Fiber axis is approximately vertical for all diffraction patterns.
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Fig. 6. TEM and X-ray fiber diffraction of non-reduced and reduced dGAE at 400 μM. (a) Electron micrographs showing the twisted features of the dGAE filaments
after incubation for 24 and 48 h. The scale bars represent 200 nm, with selected insets showing 4× magnification. (b) Diffraction pattern obtained from dGAE (400 μM)
without and with DTT.
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Fig. 7. Electron micrographs showing the detailed morphology of the dGAE assembled under non-reducing conditions, reducing conditions (400 μM) and
dGAE-C322A (100 μM). Each condition yields PHFs and some SFs. There is very little difference between the morphology of dGAE assembled under non-reducing and
reducing conditions, whereas dGAE-C322A formed twisted ribbons consisting of paired protofilaments. The scale bars are shown in nm.
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3660 PHFs formed by truncated tauno strong evidence to suggest that the structures
were different when dGAE was incubated under
non-reducing or reducing conditions. dGAE-C322A
formed twisted ribbons consisting mostly of two
protofilaments and with variable repeat lengths
392.5 ± 32.9 nm and occasionally, single protofila-
ments were observed (see Fig. 7).Discussion
In this study, we have shown that a truncated form
of tau corresponding to a 95-amino-acid region of the
C-terminal domain (dGAE) is able to form filaments
at physiological pH in the absence of any additives
and that these closely resemble the PHFs found in
neurofibrillary tangles in AD brain tissue. The dGAE
fragment matches two of the species making up
the structural core of the PHFs isolated from AD
brain tissues [2]. Using a range of biophysical and
structural approaches, we have shown that dGAE
assembles in a concentration-dependent manner,
with increasing β-sheet content and sharing the
cross-β structure characteristic of all amyloid fibrils.
Interestingly, small variations in the concentration of
the protein lead to changes in the macromolecular
appearance of the fibrils based upon electron
microscopy observations and CD spectra. This
highlights that very minor differences can have a
large effect on the packing and overall morphology of
filaments. Indeed, it has been shown that tau forms
different filament morphologies when isolated from
brain from different tauopathies, giving rise to dif-
ferent structural “strains” [40]. However, X-ray fiber
diffraction indicated that the core cross-β structure
was unaffected by these variations in macromolec-
ular assembly.
We report that the assembly of the truncated
core-tau fragment was enhanced by reducing condi-
tions and the protein was able to form longer fibrils
at the same concentration. To further explore the
contribution of disulfide bond formation, we examined
the assembly of dGAE-C322A and found that a
species lacking any cysteine residues assembles
rapidly and forms long, twisted filaments. The role for
disulfide links in assembly has previously remained
unclear as it has been impossible to study the effect
of disulfide links on assembly in the absence of
polyanionic additives, such as heparin, using full-
length recombinant tau preparations [43]. We reveal
that tau is able to form two types of dimer, one cysteine
dependent and the other, cysteine independent.
Full-length tau in COS cells has been previously
shown to form cysteine-dependent and -independent
dimers. Variants of full-length tau (C291A/C322A) that
do not contain cysteines are able to form fibrils [43].
Furukawa et al. [44] argued that the morphologies
of filaments assembled from full-length tau can be
determined by disulfide status and thioflavine-Tfluorescence and that disulfide-linked tau assembled
more readily. However, electron microscopy showed
that the filaments formed with disulfide bonds were
shorter than those formed in the presence of DTT,
similar to our findings. The K18 fragment (a different
truncated four-repeat tau fragment; tau244–372) is
able to form an intra-molecular disulfide-linked mono-
mer which is not assembly-competent [45].
Our studies suggest that a truncated tau frag-
ment corresponding to that found in the proteolyti-
cally stable core of the PHF exists in two alternative
monomeric isoforms, one with a gel mobility of
10 kDa corresponding to the theoretical molecular
weight of the fragment and a corresponding dimer of
20 kDa. The second has a gelmobility corresponding
to 12 kDa and a corresponding dimer of 24 kDa.
Exactly the same doublet was seen in the protein
extracts from the PHF-core which first permitted
the identification of a truncated tau protein fragment
as a structural constituent of the PHFs formed in AD
[2]. The formation of the 12-kDa variant does not
depend on disulfide crosslinks, since it can form in
the presence of an excess of DTT and also if there is
a C322A substitution to produce a species lacking
any cysteine residues.
The formation of the 20-kDa dimer was seen only
in preparations favorable to disulfide bridge forma-
tion using native preparations of the dGAE fragment.
Furthermore, the 10- and 20-kDa forms are enriched
in the residual supernatant fraction left after filament
assembly, whereas the 12- and 24-kDa forms are
enriched selectively from the preparations of large
aggregates isolated from slow-speed pellets. Con-
ditions that inhibit filament assembly at low concen-
tration (native dGAE at 100 μM), with formation of
elongated spherical particles and short fibers at low
concentration (100 μM), are also conditions favoring
the formation of the 20-kDa dimer. The addition of
a reducing agent (DTT) to the assembly solution
results in the ability of the short, fibrillar dGAE
structures to elongate to form long twisted fibrils.
Furthermore, preventing the formation of disulfide
bonds by replacing the only Cys residue in dGAEwith
Ala leads to the rapid formation of very long fibers.
Increasing dGAE concentration leads to formation
of long twisted fibrils, suggesting that at sufficiently
high concentration species with disulfide crosslinks
no longer affect the elongation step and that it is
possible to overcome the inhibition associated with
formation of disulfide dimers. We suggest that, at
high concentration, the nucleation process is faster
thanwhen the protein contains disulfide bonds. Since
there are no obvious differences in morphology or
structure of the filaments forming from native dGAE
at high concentration and those forming in conditions
which prevent the formation of disulfide bonds, it is
likely that there is a common assembly-competent
precursor conformation and that the resultingPHFsdo
not contain any significant amounts of disulfide-linked
3661PHFs formed by truncated taudGAE. We hypothesize that formation of assembly-
incompetent dimers via disulfide linkages competes at
the binding sites required for filament assembly,
thereby limiting their extent. From this interpretation,
conditions unfavorable to disulfide bridge formation
would facilitate the formation of the assembly-
competent variant and prevent other binding interac-
tions with assembly-incompetent dimers which im-
pede the formation of long PHF-like filaments (Fig. 8).
Our findings are consistent with the view that
disulfide bond formation impedes PHF assembly. It
has been shown that intramolecular disulfide bond
formation stabilizes aggregation-prone tau peptides
in conformations inconsistent with the formation of
cross-β-structure [45]. Our findings are therefore at
odds with the proposal that disulfide-linked dimer
formation is a critical step in the pathological aggre-
gation of tau protein in AD [44,46–48]. It is also at
odds with the proposal that the tau aggregation
inhibitor methylthioninium chloride (MTC) acts by
preventing disulfide bridge formation [49,50]. Our
data imply that if MTC were indeed able to impede
cysteine crosslinking, it would have the effect of
enhancing filament formation, which is not the case in
cell-free or cell-based models or in disaggregation of
PHFs isolated from AD brain tissue [29,51]. Further
studies aiming to elucidate the correct mechanism of
action of MTC are in progress.Fig. 8. Schematic showing the role for disulfide bonding in
At low concentration, the dGAE protein is able to form disulfide
filaments which cannot elongate further. This prevention of e
prevents formation of disulfide bonds and leads to the formation
to form long PHFs. At high concentration of dGAE in non-redu
assembly competent and incompetent forms and long filamen
bonds and is able to assemble rapidly to form long PHFs.Overall, our results show that the dGAE fragment
is able to form two different species in solution under
non-reducing conditions, an assembly-competent form
and an assembly-incompetent form. It is striking that
the 12/24-kDa variant is simultaneously enriched
in the pellet and depleted from the supernatant after
48-h incubation in conditions that reduce disulfide
bridge formation and also enhance the formation of
long fibers, which closely resemble PHFs isolated
from AD brain tissue [18,31,32]. It is also striking that
it is the same variant that is preferentially recognized
by the oligomer-specific antibody T22. Our results
suggest, therefore, that there exists a specific con-
formation present in the 12-kDa variant, which makes
it immunologically distinct from the alternative form
which migrates at 10 kDa. Filaments assembled from
the 12-kDa species have the same detailed morpho-
logical features as native PHFs isolated from AD
brain tissue, including the characteristic longitudinal
features in which four strands alternate with three
strands in the twisted ribbon configuration, and
showing only four strands in the flattened ribbon
configuration. These features reflect the presence of
the repeating C-shaped first identified in the native
PHF core [18,32] and found also to be the repeating
subunit of SFs [42]. It has been reported recently that
the C-shaped subunit of the PHF core corresponds to
a folded hairpin configuration of the core tau unit of theassembly. The initial dGAE solution contains monomers.
-linked dimers and with agitation, to elongate to form short
longation can be overcome by the addition of DTT, which
of an assembly competent intermediate that can elongate
cing conditions, there is competition between formation of
ts can be formed. dGAE-C322A is unable to form disulfide
3662 PHFs formed by truncated tauPHF matching closely the sequence of the dGAE
fragment we have studied here [31]. In this structure,
elucidated using cryo-electron microscopy analysis of
ex vivoPHFandSF, the tau folds into a cross-β/β-helix
structure in residues 306–378 [31] (Fig. S8). The
structure also reveals that the position of the Cys side
chain is buried between two sheets and would not be
available for disulfide linking with Cys from another
molecule (Fig. S8). This reinforces our findings that
the disulfide-linked dimer is assembly incompetent.
We therefore infer from the data we have presented
that the property of assembly competence that we
have associated with the 12-kDa variant is directly
linked with the hairpin conformation of the repeat
domain found in the PHF core and recognized
selectively by T22.
Previous studies have shown that the tau unit
corresponding to the dGAE fragment has the ability
to bind full-length tau with high affinity and to tem-
plate the reproduction of the core unit with loss of
proteolytically susceptible domains outside the
repeat domain in the presence of proteases [51].
The stable core of the PHF has a β-sheet structure
[3], while the fuzzy coat is thought to be composed of
unstructured protein chains [52] from the N- and
C-terminal extensions of the molecule. Although there
is considerable heterogeneity in themorphology of the
filaments formed, which we have shown to depend on
duration of incubation and concentration, the diffrac-
tion patterns of the different forms suggest a common
underlying β-sheet molecular architecture.
We hypothesize on the basis of these results that
underlying β-sheet architecture is inherent to and
located within the conformation of the assembly-
competent 12-kDa species. The property of dimer-
ization shown on SDS-PAGE is not necessarily
indicative of assembly competence and, indeed, it is
likely that formation of the 20-kDa dimer is associated
with inhibition of filament assembly. Our findings
suggest that the therapeutic goal of optimizing
inhibitors of tau aggregation may be served best by
agents that either prevent the core tau protein
fragment from adopting the assembly-competent
configuration or block the association of assembly of
12-kDa subunits into toxic oligomers and filaments.Materials and Methods
Assembly of truncated tau fibrils
Recombinant truncated tau297-391 (dGAE) and
dGAE-C322A were expressed in bacteria and
purified by P11 phosphocellulose chromatography
as described previously [51,53], with minor modifi-
cations. In some cases, 2-(N-morpholino)ethanesul-
fonic acid (Mes), pH 6.25, was used instead of
piperazine-N,N′-bis(ethanesulfonic acid) (Pipes) andthe protein was heat treated [54] instead of using
DE52 ion-exchange treatment prior to P11 chroma-
tography. Protein fractions were eluted with buffer
[50 mMPipes (pH 6.8) or 50 mMMes (pH 6.25), both
supplemented with 1 mM EGTA, 5 mM EDTA,
0.2 mM MgCl2, 5 mM 2-mercaptoethanol] containing
0.1–1 M KCl. The peak of protein elution was
identified by protein assay (at 0.3–0.5 M KCl) and
dialyzed against 80 mM Pipes buffer (pH 6.8), 1 mM
EGTA, 5 mM EDTA, 0.2 mM MgCl2, 5 mM 2-mer-
captoethanol, or PB (10 mM; pH 7.4). Protein con-
centration, measured using Advanced Protein Assay
Reagent (Cytoskeleton, Inc.) with bovine serum
albumin as a standard, was in the range 2.7–
4.9 mg/ml. The protein was diluted to 10 mM phos-
phate buffer (pH 7.4) at a range of concentrations
(100–400 μM) for further analysis.
Investigating the role of disulfide bond on
dGAE assembly
dGAE (100 μM) with and without DTT (10 mM)
was incubated at 37 °C with agitation at 700
oscillations per minute (Eppendorf thermomixer C,
Epppendorf, Germany) for 48 h. dGAE-C322A
(100 μM) was incubated using the same assembly
conditions. The assembly process was monitored
using ThS fluorescence spectroscopy, tyrosine fluo-
rescence spectroscopy, CD spectrometry, negative
stain TEM, X-ray fiber diffraction, SDS-PAGE, and
immunolabeling dot blot.
TEM
Electronmicroscopy gridswere prepared by placing
4 μl of sample onto formvar/carbon-coated 400-mesh
copper grids (Agar Scientific), blotting excess and
then washing with 4 μl of 0.22 μM filtered milliQ
water. Uranyl acetate (4 μl of 2% w/v) was placed on
the grid for 1 min and then blotted, and the grid was
allowed to air-dry. Electron micrograph images were
collected using a JEOL JEM1400-Plus Transmission
Electron Microscope operated at 120 kV. Camera is
4kx4K One View (Gatan), acquisitions were per-
formed at 25 fps and automatically corrected for drift
using Digital Micrograph (GMS3, Gatan).
CD
CD was performed using a Jasco Spectrometer
J715 and spectra collected in triplicate at a main-
tained temperature of 21 °C. Protein samples (30
and 60 μl) were placed into 0.1- and 0.2-mm path
length quartz cuvettes (Hellma), respectively, and
scanned from 180 to 300 nm. Since the CD spectra
were dominated by a random coil signal, samples
were centrifuged at 20,000g for 30 min to separate
fibrillar structures from the mixture. CD was then
determined on the supernatant and pellet fractions
3663PHFs formed by truncated tau(40 μl) separately. CD data were converted into molar
ellipticity (deg·cm2·dmol−1) where concentrations
were known.
Tyrosine fluorescence
Spectra were collected for dGAE, dGAEwith 10 mM
DTT, and dGAE-C322A (140 μl, 100 μM) in a 10-mm
cuvette. The excitation wavelength was 280 nm, and
an emission scan between wavelength 290–500 nm
was collected using a Varian Cary Eclipse Fluores-
cence Spectrophotometer. The sample compartment
was set to 21 °C with a scan rate of 600 nm/min. The
data represent three independent experiments.
ThS fluorescence
dGAE (20 μl) was mixed with ThS (280 μl, 5 μM)
in 3-(N-morpholino)propanesulfonic acid (Mops)
(20 mM, pH 6.8) and then added to a 10-mm path
length cuvette. An emission scan between 450 and
600 nm was obtained. The compartment was set to
21 °C with a scan rate of 600 nm/min. The average
of three spectra is used for each graph.
SDS-PAGE and immunoblotting
dGAE (100 μM; with or without 10 mM DTT) and
dGAE-C322A were agitated at 700 rpm, 37 °C, for
48 h. Aliquots of the whole assembly mixture were
taken at 0 and 48 h. After 48-h agitation, the whole
assembly mixture was centrifuged at 20,000g for
30 min at 4 °C. The resulting supernatant was
separated from the pellet, and the pellet was
suspended in an equal volume of PB (10 mM;
pH 7.4). The entire assembly mixture and the
supernatant and pellet fractions were used for
SDS-PAGE and immunoblotting (3 μl of each per
lane). For SDS-PAGE, samples were mixed with
SDS sample buffer (without reducing agent) and
separated using a 4%–20% gradient Mini-Protean®
TGX Precast gels (Bio-Rad) at 120 V, until the
sample buffer reached the end of the gel. The gel
was stained using Imperial Protein Stain (Thermo
Scientific), following the manufacturer's instructions,
before sealing the gel and scanning on a Canon
ImageRunner Advance 6055i scanner.
For immunoblotting, the separated proteins on the
gel were transferred onto Amersham™ Protran™
NC nitrocellulose membrane (0.45 μm) at 200 mA
for 90 min. The membranes were blocked in 5%
milk in Tris-buffered saline-Tween 20 (TBS-T;
50 mM Tris, 150 mM NaCl, pH7.4, 0.1% Tween
20) for 1 h rocking at room temperature. The
membrane was incubated with T22, an antibody
that recognizes oligomeric tau (ABN454; Merck
Millipore), in 5% milk in TBS-T (1:1000) overnight
at 4 °C. The membrane was incubated in secondary
HRP-conjugated goat anti-rabbit antibody in 5%dried milk in TBS-T (1:10,000) for 1 h at room
temperature. The membrane was developed using
Clarity™ ECL blotting substrate (Bio-Rad), following
the manufacturer's instructions, and then exposed to
X-ray film. Themembrane was washed 5 × 10 min in
TBS-T in between antibody incubations.
For the dot blot, 3 μl of the whole assembly mixture,
the supernatant and pellets were blotted onto Amer-
sham Protran NC nitrocellulose membrane (0.45 μm)
and were left to air dry. The membrane was rinsed in
TBS-T and then immediately blocked overnight at 4 °C
in 5% milk in TBS-T. The membrane was incubated
with T22 (1:1000) for 1 h at room temperature, followed
by secondary HRP-conjugated goat anti-rabbit anti-
body (1:10,000) for 1 h at room temperature. Proteins
on the membrane were detected using Clarity ECL
blotting substrate (Bio-Rad), following the manufac-
turer's instructions, and then exposed to X-ray film. The
membrane was washed 5 × 10 min in TBS-T between
each antibody incubation.
X-ray fiber diffraction
Samples were prepared for X-ray fiber diffraction by
incubating dGAE, dGAE with DTT, and dGAE-C322A
(diluted in 10 mM PB, pH 7.4) for 48 h to allow for the
formation of fibrils at 37 °C and with agitation (700
oscillations permin). The resulting fibrils were collected
by centrifugation (20,000g) and washed twice with
water to remove buffer salts, and 10 μl of the sample
was placed between wax-tipped capillary tubes
allowed to dry overnight or dried onto a Teflon slide
as described previously [55]. The partially aligned
samples were mounted on a goniometer head and a
diffraction patternwas collected using aRigaku rotating
anode fitted with Saturn CCD detector, using an
oscillation of 0.5°. Exposure times were 30 or 60 s,
and the specimen to detector distance was 50 or
100 mm, respectively. Diffraction data were converted
to TIFF format using Mosflm [56] and inspected using
CLEARER [57]. Measurements of the diffraction
signalswere taken using themodulewithinCLEARER,
and these were then entered into the unit cell deter-
mination module, to explore possible indexing of the
diffraction signals to a unit cell.Acknowledgments
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